• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Myopia Patient Case #2

Opinion
Video

Dr Noha Ekdawi presents a case of myopia management where she combines low-dose atropine with soft contact lenses.

Noha Ekdawi, MD, FAAP: My next case is a boy who I first saw in October of 2020. He had a history of Kawasaki disease but was well treated. No other family history, no other health complaints for this child. He presented at 7 years old, wearing myopic glasses, but they had increased in the past year. Parents really wanted myopia management for this child. They saw that he was already increasing. He was only 7 years old, and they wanted to start treatment. By 2020, I started everyone initially with 0.025% of atropine.

In October of 2021, I see him back, and he had increased from -1.5 in the right eye to -2.5, and in the left eye from -2 to -2.5. Not as big of an increase, but the left eye was higher anyway. Then now a year and a half on atropine, we see another increase. A diopter in the left eye and 0.75 diopters in the right eye. This is now several years on atropine, 2 years, and this child was still progressing. In June of 2022, I referred him for MiSight, and he received MiSight. This is what’s his prescription then. I saw him about 6 months later, no change. Now a year with MiSight, and now 3 years of atropine because I combined the treatments. I see no change in the prescription, maybe a 0.25 change in the left eye. The axial lengths you see here are actually better than the first case at 24.82 mm and 25.01 mm.

This is another wait and see; does my combined treatment, is that the cause of the... change or was this going to happen? This is again something we need to continue to follow. Do I need to increase my dose of atropine? We’ll have to wait and see. From 7 to 10, again, we have here with 2 forms of treatment, the MiSight and the atropine, we see no significant change. In 3 years, the total change was 1.75 diopters in each eye. Whereas multifocal contacts don’t have as good of data as MiSight contacts, it seems that MiSight contacts did do very well for this child.

Transcript is AI generated and edited for clarity and readability.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Video 2 - "Do Dry Eye Diagnostics Change the Management of Dry Eye?"
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Kelsey Roelofs, MD, details collaborative strategies for the management of thyroid eye disease
CIME 2024: Diagnostic tips and treatments for managing Demodex blepharitis
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
© 2024 MJH Life Sciences

All rights reserved.